SCOLR, Inc. is a
biopharmaceutical company with proprietary, patented
technologies and products operating in drug delivery and
nutraceuticals markets. The Company’s novel Controlled Delivery
Technology CDT™ for oral drug dosage is simple to manufacture
and offers flexible dosage release suitable for a variety of
markets (e.g. over-the-counter, prescription drugs and dietary
supplements). Needing capital to expand the development of the
CDT™, SCOLR turned to Taglich Brothers to help raise the capital
from institutional and accredited individual investors with
long-term horizons. Through a cost efficient Regulation D
Private Placement, Taglich Brothers was able to structure a deal
that was advantages to both the Company and investors.
The information
contained herein does not constitute a solicitation of any order
to buy or sell any securities. The information provided herein may
be displayed and printed for your personal, noncommercial use
only. You may not reproduce, retransmit, distribute, disseminate,
sell, publish, broadcast or circulate the information to anyone,
without the express written consent of Taglich Brothers, Inc.
